+

WO2018183808A9 - Antiviral therapeutic - Google Patents

Antiviral therapeutic Download PDF

Info

Publication number
WO2018183808A9
WO2018183808A9 PCT/US2018/025350 US2018025350W WO2018183808A9 WO 2018183808 A9 WO2018183808 A9 WO 2018183808A9 US 2018025350 W US2018025350 W US 2018025350W WO 2018183808 A9 WO2018183808 A9 WO 2018183808A9
Authority
WO
WIPO (PCT)
Prior art keywords
rnas
mrna encoding
cas endonuclease
guide
present disclosure
Prior art date
Application number
PCT/US2018/025350
Other languages
French (fr)
Other versions
WO2018183808A1 (en
Inventor
Derek D. Sloan
Sarah LEDOUX
Xin Cindy XIONG
Michael Patrick HOUSLEY
Original Assignee
Agenovir Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenovir Corporation filed Critical Agenovir Corporation
Priority to CN201880035095.7A priority Critical patent/CN110678548A/en
Priority to JP2019553095A priority patent/JP2020515258A/en
Priority to EP18721530.6A priority patent/EP3601568A1/en
Publication of WO2018183808A1 publication Critical patent/WO2018183808A1/en
Publication of WO2018183808A9 publication Critical patent/WO2018183808A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present disclosure provides guide RNAs for use in cleaving target viral nucleic acids. The present disclosure further provides compositions that include an mRNA encoding a Cas endonuclease and a guide RNA having particular sequences and modifications, with both RNAs encapsulated by nanoparticles, for the treatment of HPV infection. In some embodiments, the guide RNAs and mRNA encoding a Cas endonuclease are packaged in a lipid nanoparticle, which may be suspended in a carrier formulation for topical or local delivery to infected tissue. In some embodiments, the guide RNA and/or the mRNA encoding the Cas endonuclease also include features such as modified nucleotides that promote the delivery of the RNAs to, and retention within, infected cells.
PCT/US2018/025350 2017-03-31 2018-03-30 Antiviral therapeutic WO2018183808A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201880035095.7A CN110678548A (en) 2017-03-31 2018-03-30 Antiviral therapeutic agent
JP2019553095A JP2020515258A (en) 2017-03-31 2018-03-30 Antiviral therapeutic agent
EP18721530.6A EP3601568A1 (en) 2017-03-31 2018-03-30 Antiviral therapeutic

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762479643P 2017-03-31 2017-03-31
US62/479,643 2017-03-31
US201762507963P 2017-05-18 2017-05-18
US62/507,963 2017-05-18

Publications (2)

Publication Number Publication Date
WO2018183808A1 WO2018183808A1 (en) 2018-10-04
WO2018183808A9 true WO2018183808A9 (en) 2018-12-13

Family

ID=62092242

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/025350 WO2018183808A1 (en) 2017-03-31 2018-03-30 Antiviral therapeutic

Country Status (4)

Country Link
EP (1) EP3601568A1 (en)
JP (1) JP2020515258A (en)
CN (1) CN110678548A (en)
WO (1) WO2018183808A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014296278C1 (en) 2013-07-30 2023-02-02 Genevant Sciences Gmbh Block copolymers and their conjugates or complexes with oligonucleotides
CN114642735A (en) 2015-01-21 2022-06-21 菲泽尔克斯公司 Methods, compositions and systems for delivering therapeutic and diagnostic agents into cells
EP3562510A4 (en) 2016-12-30 2021-01-06 Genevant Sciences GmbH Branched peg molecules and related compositions and methods
US11781125B2 (en) * 2017-12-15 2023-10-10 Danisco Us Inc. Cas9 variants and methods of use
WO2020154594A2 (en) * 2019-01-25 2020-07-30 Agenovir Corporation Compositions and methods for treatment of human papillomavirus
CN111748551B (en) * 2019-03-27 2021-07-09 纳昂达(南京)生物科技有限公司 Blocking sequence, capture kit, library hybridization capture method and library construction method
WO2021168266A1 (en) * 2020-02-21 2021-08-26 Temple University - Of The Commonwealth System Of Higher Education Eradication of merkel cell polyomavirus
CN111440825A (en) * 2020-04-07 2020-07-24 嘉晨西海(杭州)生物技术有限公司 Method for loading mRNA (messenger ribonucleic acid) by liposome
CA3179862A1 (en) 2020-04-09 2021-10-14 Verve Therapeutics, Inc. Base editing of angptl3 and methods of using same for treatment of disease
WO2021229502A1 (en) * 2020-05-15 2021-11-18 Crispr Therapeutics Ag Messenger rna encoding cas9 for use in genome-editing systems
CN111534518B (en) * 2020-05-18 2021-07-23 纳昂达(南京)生物科技有限公司 Universal blocking sequence and application thereof
CA3205133A1 (en) * 2020-12-15 2022-06-23 Flagship Pioneering Innovations V, Inc. Compositions and methods for modulating myc expression
WO2022240960A1 (en) * 2021-05-14 2022-11-17 Crispr Therapeutics Ag Mrna large scale synthesis and purification

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057725T2 (en) 2011-10-03 2022-06-28 Modernatx Inc Modified nucleosides, nucleotides and nucleic acids and their uses
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
SMT202100691T1 (en) 2013-07-11 2022-01-10 Modernatx Inc Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
EP3107999A4 (en) * 2014-02-18 2017-10-04 Duke University Compositions for the inactivation of virus replication and methods of making and using the same
US10900034B2 (en) 2014-12-03 2021-01-26 Agilent Technologies, Inc. Guide RNA with chemical modifications
AU2015364282B2 (en) * 2014-12-18 2021-04-15 Integrated Dna Technologies, Inc. CRISPR-based compositions and methods of use
MA41349A (en) * 2015-01-14 2017-11-21 Univ Temple RNA-GUIDED ERADICATION OF HERPES SIMPLEX TYPE I AND OTHER ASSOCIATED HERPES VIRUSES
KR20240038141A (en) * 2015-04-06 2024-03-22 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Chemically modified guide rnas for crispr/cas-mediated gene regulation
JP2018516984A (en) * 2015-05-29 2018-06-28 アジェノビア コーポレーション Compositions and methods for cell targeted HPV treatment
RU2752834C2 (en) * 2015-06-18 2021-08-09 Те Брод Инститьют, Инк. Crispr enzyme mutations reducing non-targeted effects

Also Published As

Publication number Publication date
CN110678548A (en) 2020-01-10
EP3601568A1 (en) 2020-02-05
WO2018183808A1 (en) 2018-10-04
JP2020515258A (en) 2020-05-28

Similar Documents

Publication Publication Date Title
WO2018183808A9 (en) Antiviral therapeutic
BR112019002117A2 (en) rnai agent against hepatitis b virus infection
WO2021159130A3 (en) Coronavirus rna vaccines and methods of use
WO2022221359A8 (en) Epstein-barr virus mrna vaccines
MX2024005653A (en) MODIFIED DOUBLE-STRANDED RIBONUCLEIC ACID (RNA) AGENTS.
WO2016145008A3 (en) Mirna for treatment of breast cancer
MX385869B (en) MODIFIED RNA AGENTS.
MX2015011943A (en) RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS.
WO2015042308A3 (en) Rna-based hiv inhibitors
MX2020011807A (en) Compositions and methods for inhibiting gene expression of hepatitis b virus.
PE20211393A1 (en) ARNi COMPOSITIONS AGAINST COMPLEMENT COMPONENT C5 AND METHODS FOR ITS USE
MX2015010083A (en) Biodegradable and clinically-compatible nanop articles as drug delivery carriers.
EA201490563A1 (en) ANTI-SMALL OLIGONUCLEOTIDE FOR THE TREATMENT OF CONGENITAL LEAVER AMAUROSIS
JP2013046616A5 (en)
WO2014111876A3 (en) Modulation of mitophagy and use thereof
EP4410373A3 (en) Nucleic acid simultaneously inhibiting expression of mtor gene and stat3 gene
MX2013010524A (en) Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer.
IN2014CN03921A (en)
MX348555B (en) Prophylactic or therapeutic agent for fibrosis.
BR112015022308A8 (en) antisense oligonucleotides for the treatment of cancer stem cells
MX2016000021A (en) Dengue virus-specific sirna, double helix oligo-rna structure comprising sirna, and composition for suppressing proliferation of dengue virus comprising rna structure.
WO2020154594A3 (en) Compositions and methods for treatment of human papillomavirus
WO2011103028A3 (en) Compositions and methods for inhibiting mmset
PH12018502320A1 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
WO2011087343A3 (en) Composition for treating cancer related to an hpv infection

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18721530

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019553095

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2018721530

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2018721530

Country of ref document: EP

Effective date: 20191031

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载